Studies of the adduct formed on interacting cisplatin with human apotransferrin: Synthesis, in vitro binding kinetics, in vivo pharmacokinetics and biodistribution in the rat. by Hoeschele, James D. et al.
METALS IN MEDICINE 417 
F040 STUDIES OF THE ADDUCT FORMED ON INTERACT- 
ING CISPLATIN WITH HUMAN APOTRANSFERRIN: 
SYNTHESIS, IN VITRO BINDING KINETICS, IN VIVO 
PHARMACOKINETICS AND BIODISTRIBUTION IN THE RAT. 
J.D. Hoeschelea L.R. Whitfield,b W.R. Leopold,b W. 
McNally,b J. Nawrocki,b J. Phillips,C a Department of Chemistry, 
University of Michigan, Ann Arbor, MI, 48109-I 055 b Parke-Davis 
Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, MI 
48105 and C Cancer Therapy and Research Foundation of South Texas, San 
Antonio, TX 78229. 
Transferrins are glycoproteins which are important in the cellular trans- 
port and storage of iron and other metal ions into cells [ 11. Since many tumor 
cells overproduce transferrin receptors, an attractive concept is to consider 
using transferrin as a delivery system to target cancer drugs specifically to 
tumor cells. We have undertaken a test of this concept using a cisplatin(cisPt)- 
apotrans- ferrin(aTf) adduct which was (1) synthesized, isolated (via dialysis), 
and analyzed via 1g5mPt radioactivity, (2) tested in vivo for antitumor activity 
vs implanted M5076 ovarian sarcoma tumors in the mouse, and (3) used to 
study the pharmacokinetic and biodistribution properties in vivo for compar- 
ison with those of cisplatin. 
The results and conclusions are as follows: (1) CisPt reacts with 
human aTf with an apparent first-order rate constant of -2x10-5 set-l. Since 
this rate constant is comparable to that for the aquation reaction of cisPt, it is 
likely that the reaction proceeds via an aquation intermediate. (2) The isolated 
adduct is non-stoichiometric with an approximate empirical formula of Pt~.41- 
0_75Tf. (A Pt/Tf ratio of 1.8-2.0 would be expected if the cisPt-aTf reaction 
went to completion and cisPt occupied both available Fe@) binding sites.) 
(3) The cisPt-aTf adduct is inactive against murine M5076 ovarian sarcoma 
over a wide range of dose levels (799-3318 mg as Tf/Kg body weight), 
indicating that active cisPt is not being delivered via the adduct. (4) The cisPt- 
aTf adduct is a unique entity which exhibits pharmacokinetic and biodistribu- 
tion properties distinctly different from those of cispt. 
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